Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

PHASE3UnknownINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

May 31, 2006

Conditions
Metastatic Colorectal CancerColon CancerRectal Cancer
Interventions
DRUG

5- Fluorouracil (5-FU)

DRUG

bevacizumab (Avastin)

DRUG

Leucovorin

DRUG

CoFactor (ANX-510)

Trial Locations (47)

95819

Mercy General Hospital, Sacramento

Unknown

Research Center In, Florence

Research Center In, Anaheim

Research Center In, Apple Valley

Research Center In, Beverly Hills

Research Center In, Irvine

Research Center In, Mission Hills

Research Center In, Poway

Research Center In, Rancho Mirage

Research Center In, Sacramento

Research Center In, San Diego

Research Site In, San Diego

Research Center In, Vista

Research Center In, Boynton Beach

Research Center In, Merritt Island

Research Center In, Port Saint Lucie

Research Center In, Tarpon Springs

Research Center In, Gurnee

Research Center In, Joliet

Research Center In, Skokie

Research Center In, Indianapolis

Research Center In, Wichita

Research Center In, Hazard

Research Center In, Baltimore

Research Center In, Flint

Research Center In, Free Soil

Research Center In, Grand Rapids

Research Center In, Port Huron

Research Center In, Jackson

Research Center In, Henderson

Research Center In, Las Vegas

Research Center In, Reno

Research Center In, Cherry Hill

Research Center In, Farmington

Research Center In, East Setauket

Research Center In, Greenville

Research Center In, Middletown

Research Center In, Cranston

Research Center In, Charleston

Research Center In, Columbia

Research Center In, Chattanooga

Research Center In, Collierville

Research Center In, Fort Worth

Research Center In, Ogden

Research Center In, Lacey

Research Center In, Walla Walla

Research Center In, Zrenjanin

Sponsors
All Listed Sponsors
lead

Mast Therapeutics, Inc.

INDUSTRY

NCT00337389 - Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. | Biotech Hunter | Biotech Hunter